Pipeline
JangoBio is building a regenerative medicine pipeline that combines established revenue-generating businesses, near-term veterinary commercialization, and the long-term development of human therapeutics. Our strategy is designed to generate revenue and build commercial capabilities while advancing innovative cell-based therapies for animal and human health.
JangoCell & JangoDx
JangoBio’s operating subsidiaries provide an established foundation for growth. JangoCell delivers specialized cell biology products and contract research services to biotechnology, pharmaceutical, and academic clients. JangoDx provided diagnostic and healthcare testing services during the COVID-19 pandemic, generating an additional source of revenue during that period.
JangoPet – Jango-Renew for Canine Osteoarthritis
Our primary near-term commercial focus is Jango-Renew, JangoPet’s regenerative cell therapy for canine osteoarthritis. Jango-Renew is an allogeneic adipose-derived stem cell therapy designed to regenerate joints and improve mobility and comfort in dogs with OA.
JangoPet is advancing Jango-Renew through clinical development toward commercialization. This program provides JangoBio with an opportunity to enter the veterinary regenerative medicine market while building the clinical, regulatory, manufacturing, and commercial capabilities needed to support our broader therapeutic pipeline.
Expanding Our Regenerative Medicine Platform
Beyond Jango-Renew, JangoBio is developing next-generation regenerative technologies, including hormone-producing organoids designed to restore endocrine function, treat the symptomology of menopause/andropause, mitigate diseases of aging and extend our healthy longevity. These programs expand our platform beyond individual cell therapies toward biologic systems capable of providing sustained physiological regulation.
JangoMed
JangoMed is JangoBio’s human therapeutics subsidiary, focused on translating our veterinary regenerative medicine and organoid technologies into therapies for human health.
Our long-term strategy is to leverage the scientific, clinical, manufacturing, regulatory, and commercial foundation established through JangoPet and JangoCell to advance these technologies toward human clinical development. Revenue from commercial products, services, licensing, and strategic partnerships can help support continued development of JangoBio’s human therapeutic pipeline.